Avoro Capital Advisors LLC's Form 4 filing
Scribe Therapeutics, Inc.SCTX · filed Jul 28, 2026
- Accession no.
- 0000902664-26-003270
- Filed
- Jul 28, 2026, 9:30 PM ET
- Trade date
- Jul 24-28, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $36.3M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Avoro Capital Advisors LLCCIK 0001633313 | Director, 10% Owner, Other: See Remarks |
| Aghazadeh BehzadCIK 0001701815 | Director, 10% Owner, Other: See Remarks |
| Avoro Ventures LLCCIK 0001879253 | Director, Other: See Remarks |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 24, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +2,333,333 | $15.00F1 | +$34,999,995 | 3,030,983 | Indirect | |
| Jul 24, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +50,000 | $22.31F2 | +$1,115,500 | 3,080,983 | Indirect | |
| Jul 28, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +7,905 | $18.25F2 | +$144,266.25 | 3,088,888 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the "IPO") at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC ("Avoro Life Sciences") and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. ("Avoro Ventures Fund" and, together with Avoro Life Sciences, the "Funds").
Referenced by the price of 1 transaction in Table I.
- F2
The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
Referenced by the price of 2 transactions in Table I.
Remarks
Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.